New combination malaria treatment equally effective

April 5, 2012
New combination malaria treatment equally effective

(HealthDay) -- Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection, according to a study published in the April 5 issue of the New England Journal of Medicine.

Ronnatrai Rueangweerayut, M.D., from Mae Sot General Hospital in Tak, Thailand, and colleagues randomly assigned 1,271 patients from Asia or Africa (3 to 60 years old) with confirmed uncomplicated Plasmodium falciparum (P. falciparum) malaria to a fixed-dose combination of 180 mg pyronaridine plus 60 mg artesunate (848 patients) or 250 mg mefloquine plus 100 mg artesunate (423 patients) once daily for three days.

Based on the end point of adequate clinical and parasitological response on day 28, corrected for reinfection, in the per-protocol population, the researchers found that efficacy was similar for the two groups, at 99.2 percent in the pyronaridine-artesunate group and 97.8 percent for the mefloquine plus artesunate group. In the intention-to-treat population, efficacy on day 42 was 83.1 percent in the pyronaridine-artesunate group and 83.9 percent in the mefloquine plus artesunate group. Among the 211 Cambodian patients, median parasite clearance times were significantly longer in both groups.

"Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria," Rueangweerayut and colleagues conclude. "In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin."

The study was supported by a public-private partnership between Shin Poong Pharmaceutical Company and Medicines for Malaria Venture; several authors disclosed financial ties to the latter.

More information: Full Text (subscription or payment may be required)

Related Stories

Pyramax receives positive opinion from the EMA

February 21, 2012

Pyramax, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.